Landscape Capital Management L.L.C. Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

Landscape Capital Management L.L.C. reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 69.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,351 shares of the medical device company's stock after selling 43,647 shares during the period. Landscape Capital Management L.L.C.'s holdings in DexCom were worth $1,505,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in DXCM. Versant Capital Management Inc purchased a new stake in shares of DexCom in the 4th quarter worth $25,000. Private Trust Co. NA raised its stake in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after buying an additional 245 shares during the period. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC purchased a new stake in DexCom in the 4th quarter worth approximately $38,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DXCM shares. Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Mizuho started coverage on DexCom in a research note on Thursday. They issued an "outperform" rating and a $85.00 price target for the company. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

Remove Ads

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock worth $8,044,178 over the last 90 days. Company insiders own 0.30% of the company's stock.

DexCom Trading Up 0.5 %

Shares of NASDAQ DXCM traded up $0.36 during trading hours on Thursday, hitting $67.20. 4,853,661 shares of the company traded hands, compared to its average volume of 4,101,318. The company's 50 day moving average price is $77.74 and its 200 day moving average price is $76.63. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $141.25. The stock has a market capitalization of $26.35 billion, a price-to-earnings ratio of 46.99, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.